Quote:

---

It looks like on Merck's website they are currently recruiting for a couple CRC trials.

---

I took a look at those trials.

One is a solid tumor basket trial including CRC that just uses Keytruda. We know leronlimab does what Keytruda does.

One is a solid tumor basket trial that uses Keytruda and Belzutifan which inhibits HIF-2a. HIF-1a was on the leronlimab regulator list but not HIF-2a. I took a look at the HIF-2a pathway and leronlimab would downregulate it via downregulation of NF-kb.

The third trial is in CRC but it's looking at microsatellite instability CRC rather than microsatellite stable CRC like our trial. Merck's trial pairs Keytruda with Quavonlimab which blocks CTLA-4. CTLA-4 is on the leronlimab regulator list.

Merck's going about this all wrong. They need a trial pairing Keytruda with a couple of dozen drugs then they can approach what leronlimab does.